Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Connective Tissue Disorder Clear all
Completed Not applicable Interventional Results available

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

NCT00656669
View directory record Official record
Conditions
Breast Cancer
Interventions
sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 8:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Connective Tissue Motion Measure 2

NCT01784094
View directory record Official record
Conditions
Low Back Pain, Musculoskeletal Pain
Interventions
StromaGlide
Device
Lead sponsor
Stromatec, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring

NCT04559022
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic, Acne
Interventions
Fat Grafting
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 1 Interventional

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 25, 2026, 8:00 PM EDT
Terminated Phase 2Phase 3 Interventional

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

NCT01189253
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 2 Interventional

Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00003539
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

NCT03154281
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
niraparib, everolimus
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jun 25, 2026, 8:00 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 8:00 PM EDT
Not listed No phase listed Observational

Dermatomyositis and Polymyositis Registry

NCT01637064
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Acthar
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 25, 2026, 8:00 PM EDT
Completed No phase listed Observational

Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers

NCT01971957
View directory record Official record
Conditions
Sjogren-Larsson Syndrome (SLS)
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 25, 2026, 8:00 PM EDT
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Bacterial Decolonization to Prevent Radiation Dermatitis

NCT03883828
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Chlorhexidine gluconate solution, Mupirocin Ointment
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 3 Interventional

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

NCT03073967
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, Investigator's choice
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
16 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 8:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

NCT05968144
View directory record Official record
Conditions
Prostatic Neoplasm, Survivorship, Frailty, Aging, Metastatic Breast Cancer
Interventions
Dietary recommendations, Time-restricted eating
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Empowering Latinas to Obtain Breast Cancer Screenings

NCT02964234
View directory record Official record
Conditions
Breastcancer, Breast Diseases
Interventions
Empowerment, Education
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
52 Years to 75 Years · Female only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jun 25, 2026, 8:00 PM EDT
Completed No phase listed Observational Results available

A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System

NCT02036931
View directory record Official record
Conditions
Noninflammatory Degenerative Joint Disease, Rheumatoid Arthritis
Interventions
Metal on Polyethylene articulation, Ceramic on Polyethylene articulation, Ceramic on Ceramic articulation
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 25, 2026, 8:00 PM EDT
Recruiting Not applicable Interventional

Kawasaki MATCH Trial

NCT07291245
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Kawasaki MATCH
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Days to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 25, 2026, 8:00 PM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jun 25, 2026, 8:00 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

NCT03712228
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Factor XIIa antagonist monoclonal antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jun 25, 2026, 8:00 PM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 25, 2026, 8:00 PM EDT
Active, not recruiting Phase 1 Interventional

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

NCT01364051
View directory record Official record
Conditions
Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
Interventions
Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, Selumetinib Sulfate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 8:00 PM EDT